Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H.
Jansen B, et al.
Lancet. 2000 Nov 18;356(9243):1728-33. doi: 10.1016/S0140-6736(00)03207-4.
Lancet. 2000.
PMID: 11095261
Clinical Trial.